**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**WASHINGTON,      D.C. 20549**

**FORM      10-Q**

| x | QUARTERLY                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934. |
|---|------------------------------------------------------------------------------------------------------------------|

| o | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE                ACT |
|---|-----------------------------------------------------------------------------------------------|

**NUTRA      PHARMA CORP.**

| **California**                                               | **91-2021600**                                      |
|--------------------------------------------------------------|-----------------------------------------------------|
| (State                or Other Jurisdiction of Organization) | (IRS                Employer Identification Number) |

**791      Park of Commerce Blvd, Suite 300, Boca Raton, FL 33487**

**(954)      509-0911**

| Large                accelerated filer o | Accelerated                filer o         |
|------------------------------------------|--------------------------------------------|
| Non-accelerated                filer o   | Smaller                reporting company x |

----

| PART                I. FINANCIAL INFORMATION                                                                                      |                                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                              |                                                                                                                                             |   |
| Item                1. Financial Statements                                                                                       |  3                                                                                                                                          |
|                                                                                                                              |                                                                                                                                             |   |
|                                                                                                                              | Consolidated                Balance Sheets as of June 30, 2008 (Unaudited) and December 31,                2007                                  |  3 |
|                                                                                                                              |                                                                                                                                             |   |
|                                                                                                                              | Consolidated                Statements of Operations for the three months ended June 30, 2008                and 2007                (Unaudited) | 4 |
|                                                                                                                              |                                                                                                                                             |   |
|                                                                                                                              | Consolidated                Statements of Cash Flows for the three months ended June 30, 2008                and 2007                (Unaudited) |  5 |
|                                                                                                                              |                                                                                                                                             |   |
|                                                                                                                              | Notes                to Unaudited Consolidated Financial Statements                                                                              |  6 |
|                                                                                                                              |                                                                                                                                             |   |
| Item                2. Management’s Discussion and Analysis of Financial Condition and Results                of Operations |  10                                                                                                                                         |
|                                                                                                                              |                                                                                                                                             |   |
| Item                3. Quantitative and Qualitative Disclosures about Market                Risk                                  | 17                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |   |
| Item                4T. Controls and Procedures                                                                                   | 17                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |
| PART                II. OTHER INFORMATION                                                                                         |                                                                                                                                             |
|                                                                                                                              |                                                                                                                                             |   |
| Item                1. Legal Proceedings                                                                                          | 18                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |   |
| Item                2. Unregistered Sales of Equity Securities and Use of                Proceeds                                 | 18                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |   |
| Item                5. Other Information                                                                                          | 18                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |   |
| Item                6. Exhibits                                                                                                   | 20                                                                                                                                               |
|                                                                                                                              |                                                                                                                                             |   |
| SIGNATURES                                                                                                                        | 20                                                                                                                                               |

----

**Part      I.**
** **
**Financial      Information **

**Item      1. **
**Financial      Statements**

|                                                                                                                                                                                    |   | **June                  30,** **2008** |        | **December                  31,****2007** |   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------------------------------------|-------------|-------------------------------------------|--------|
|                                                                                                                                                                                    |   | **(Unaudited)**                             |        |                                      |   |
| ASSETS                                                                                                                                                                                  |   |                                        |        |                                      |   |   |   |
| Current                  assets:                                                                                                                                                        |   |                                        |        |                                      |   |   |   |
| Cash                                                                                                                                                                                    |   | $                                           | 43,411      |                                      | $      | 122,810 |   |
| Inventory                                                                                                                                                                               |   |                                        | 11,425      |                                      |   | 11,425 |   |
| Prepaid                  expenses                                                                                                                                                       |   |                                        | 25,514      |                                      |   | - |   |
| Total                  current assets                                                                                                                                                   |   |                                        | 80,350      |                                      |   | 134,235 |   |
| Property                  and equipment, net                                                                                                                                            |   |                                        | 14,455      |                                      |   | - |   |
| Goodwill                                                                                                                                                                                |   |                                        | 2,397,749   |                                      |   | - |   |
| Other                  assets                                                                                                                                                           |   |                                        | 8,133       |                                      |   | 9,950 |   |
| TOTAL                  ASSETS                                                                                                                                                           |   | $                                           | 2,500,687   |                                      | $      | 144,185 |   |
|                                                                                                                                                                                    |   |                                        |        |                                      |   |   |   |
| LIABILITIES                  AND STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                         |   |                                        |        |                                      |   |   |   |
| Current                  liabilities:                                                                                                                                                   |   |                                        |        |                                      |   |   |   |
| Accounts                  payable                                                                                                                                                       |   | $                                           | 130,053     |                                      | $      | 22,496 |   |
| Accrued                  expenses                                                                                                                                                       |   |                                        | 737,289     |                                      |   | 30,000 |   |
| Due                  to officers                                                                                                                                                        |   |                                        | 1,324,279   |                                      |   | 1,944,414 |   |
| Other                  loans payable                                                                                                                                                    |   |                                        | 100,300     |                                      |   | 100,000 |   |
| Total                  current liabilities                                                                                                                                              |   |                                        | 2,291,921   |                                      |   | 2,096,910 |   |
|                                                                                                                                                                                    |   |                                        |        |                                      |   |   |   |
| Stockholders'                  equity (deficit):                                                                                                                                        |   |                                        |        |                                      |   |   |   |
| Common                  stock, $0.001 par value, 2.0 billion shares authorized 186,135,682                  and                  81,895,682 shares issued and outstanding, respectively |   |                                        | 186,136     |                                      |   | 81,896 |   |
| Additional                  paid-in capital                                                                                                                                             |   |                                        | 21,106,232  |                                      |   | 18,074,473 |   |
| (Deficit)                  accumulated during the development stage                                                                                                                     |   |                                        | (21,083,602 | )                                         |   | (20,109,094 | ) |
| Total                  stockholders' equity (deficit)                                                                                                                                   |   |                                        | 208,766     |                                      |   | (1,952,725 | ) |
| TOTAL                  LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)                                                                                                                   |   | $                                           | 2,500,687   |                                      | $      | 144,185 |   |

----

NUTRA        PHARMA CORP.

|                                                                   |   |                                            |       |                                          |   |                             |   |   |       | For                  the     |   |
|------------------------------------------------------------------------|--------|-------------------------------------------------|------------|-----------------------------------------------|--------|----------------------------------|--------|--------|------------|------------------------------|--------|
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       | Period                  From |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       | February                  1, |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       | 2000                         |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       | (Inception)                  |   |
|                                                                   |   | Three Months Ended June 30, |       | Six Months Ended June 30, |   | ThroughJune                  30, |   |
|                                                                   |   | 2007                                            |       | 2008                                          |   | 2007                             |   | 2008   |       | 2008                         |   |
| Sales                                                                  |   | $                                               | -          |                                          | $      | -                                |   | $      | -          |                         | $      | - |   | $ | 20,200 |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| Cost                  of sales                                         |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 3,472 |   |
| Gross                  profit                                          |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 16,728 |   |
| Costs                  and expenses:                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| General                  and administrative                            |   |                                            | 2,161      |                                          |   | 342,233                          |   |   | 315,131    |                         |   | 519,517 |   |   | 7,462,910 |   |
| Research                  and development                              |   |                                            | (47,179    | )                                             |   | -                                |   |   | -          |                         |   | - |   |   | 1,740,237 |   |
| General                  and administrative - stock based compensation |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | 425,000 |   |   | 7,354,657 |   |
| Write-off                  of advances to potential acquiree           |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 629,000 |   |
| Finance                  costs                                         |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 786,000 |   |
| Interest                  expense                                      |   |                                            | 18,123     |                                          |   | 14,302                           |   |   | 34,135     |                         |   | 29,991 |   |   | 426,050 |   |
| Amortization                  of license agreement                     |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 155,210 |   |
| Amortization                  of intangibles                           |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 656,732 |   |
| Losses                  on settlements                                 |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 1,261,284 |   |
| Write-down                  of investment in subsidiary                |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 620,805 |   |
| Equity                  in loss of unconsolidated subsidiary           |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 853,540 |   |
| Write-off                  of investment in Portage BioMed             |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 60,000 |   |
| Write-off                  of investment in Xenacare                   |   |                                            | -          |                                          |   | -                                |   |   | -          |                         |   | - |   |   | 175,000 |   |
| Net                  gain from deconsolidation of Receptopharm         |   |                                            | (1,081,095 | )                                             |   | -                                |   |   | (1,081,095 | )                            |   | - |   |   | (1,081,095 | ) |
| Total                  costs and expenses                              |   |                                            | (1,107,990 | )                                             |   | 356,535                          |   |   | (731,829   | )                            |   | 974,508 |   |   | 21,100,330 |   |
| Net                  income (loss)                                     |   | $                                               | 1,107,990  |                                          | $      | (356,535                         | )      | $      | 731,829    |                         | $      | (974,508 | ) | $ | (21,083,602 | ) |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| Net                  income (loss) per common share - basic            |   | $                                               | 0.02       |                                          | $      | (0.00                            | )      | $      | 0.01       |                         | $      | (0.01 | ) |   |   |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| Net                  income (loss) per common share - diluted          |   | $                                               | 0.02       |                                          | $      | (0.00                            | )      | $      | 0.01       |                         | $      | (0.01 | ) |   |   |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| Weighted                  average common shares outstanding - basic    |   |                                            | 73,500,462 |                                          |   | 184,221,396                      |   |   | 73,391,179 |                         |   | 135,769,858 |   |   |   |   |
|                                                                   |   |                                            |       |                                          |   |                             |   |   |       |                         |   |   |   |   |   |   |
| Weighted                  average common shares outstanding - diluted  |   |                                            | 73,500,462 |                                          |   | 184,221,396                      |   |   | 73,391,179 |                         |   | 135,769,858 |   |   |   |   |

----

NUTRA        PHARMA CORP.

|                                                                   |   |                                       |     |                             |   | For                  the     |   |
|------------------------------------------------------------------------|--------|--------------------------------------------|----------|----------------------------------|--------|------------------------------|--------|
|                                                                   |   |                                       |     |                             |   | Period                  From |   |
|                                                                   |   |                                       |     |                             |   | February                  1, |   |
|                                                                   |   |                                       |     |                             |   | 2000                         |   |
|                                                                   |   |                                       |     |                             |   | (Inception)                  |   |
|                                                                   |   |                                       |     |                             |   | Years                  Ended |   |
|                                                                   |   | Six                  Months Ended June 30, |     | ThroughJune                  30, |   |
|                                                                   |   | 2007                                       |     | 2008                             |   | 2008                         |   |
|                                                                   |   |                                       |     |                             |   |                         |   |
| Cash                  flows from operating activities:                 |   |                                       |     |                             |   |                         |   |   |   |   |
| Net                  cash (used in) operating activities               |   | $                                          | (479,650 | )                                | $      | (490,843                     | )      | $ | (6,178,955 | ) |
| Cash                  flows from investing activities:                 |   |                                       |     |                             |   |                         |   |   |   |   |
| Cash                  reduction due to deconsolidation of Infectech    |   |                                       | -        |                             |   | -                            |   |   | (2,997 | ) |
| Cash                  reduction due to deconsolidation of Receptopharm |   |                                       | -        |                             |   | -                            |   |   | (1,754 | ) |
| Cash                  acquired in acquisition of Infectech             |   |                                       | -        |                             |   | -                            |   |   | 3,004 |   |
| Cash                  acquired in acquisition of Receptopharm          |   |                                       |     |                             |   | 40,444                       |   |   | 40,444 |   |
| Acquisition                  of property and equipment                 |   |                                       | -        |                             |   | -                            |   |   | (96,029 | ) |
| Loan                  to Receptopharm                             |   |                                       | -        |                             |   | (300,000                     | )      |   | (300,000 | ) |
| Investments                  carried at cost                           |   |                                       | -        |                             |   | -                            |   |   | (235,000 | ) |
| Net                  cash (used in) investing activities               |   |                                       | -        |                             |   | (259,556                     | )      |   | (592,332 | ) |
|                                                                   |   |                                       |     |                             |   |                         |   |   |   |   |
| Cash                  flows from financing activities:                 |   |                                       |     |                             |   |                         |   |   |   |   |
| Common                  stock issued for cash                          |   |                                       | -        |                             |   | 461,000                      |   |   | 3,260,500 |   |
| Proceeds                  from convertible loans                       |   |                                       | -        |                             |   | -                            |   |   | 304,750 |   |
| Proceeds                  from notes payable                           |   |                                       | -        |                             |   | -                            |   |   | 100,000 |   |
| Loans                  from stockholders, net of repayments            |   |                                       | 468,203  |                             |   | 210,000                      |   |   | 3,149,448 |   |
| Net                  cash provided by financing activities             |   |                                       | 468,203  |                             |   | 671,000                      |   |   | 6,814,698 |   |
| Net                  increase (decrease) in cash                       |   |                                       | (11,447  | )                                |   | (79,399                      | )      |   | 43,411 |   |
| Cash                  - beginning of period                            |   |                                       | 11,447   |                             |   | 122,810                      |   |   | - |   |
| Cash                  - end of period                                  |   | $                                          | -        |                             | $      | 43,411                       |   | $ | 43,411 |   |

----

----

| Total                  number of Nutra Pharma shares issued                  |   |   | 30,000,000 |   |
|------------------------------------------------------------------------------|--------|--------|------------|--------|
| Market                  price of Nutra Pharma common stock on April 10, 2008 |   | $      | 0.035      |   |
| Value                  of shares issued                                      |   | $      | 1,050,000  |   |
| Loan                  to Receptopharm forgiven at closing                    |   |   | 300,000    |   |
| Liabilities                  of Receptopharm assumed at closing              |   |   | 1,119,413  |   |
| Total                  purchase cost to be allocated                         |   | $      | 2,469,413  |   |
|                                                                         |   |   |       |   |
| Allocation                  of purchase cost:                                |   |   |       |   |
| Fair                  value of Receptopharm assets at closing                |   | $      | 71,664     |   |
| Purchase                  cost in excess of fair value of assets acquired    |   |   | 2,397,749  |   |
| Total                  purchase cost                                         |   | $      | 2,469,413  |   |

----

| Net                  losses included in the consolidated financial statements |   | $      | 4,056,095  |   |
|-------------------------------------------------------------------------------|--------|--------|------------|--------|
| Investment                  advances and equity method losses                 |   |   | (2,975,000 | )      |
| Gain                  on deconsolidation                                      |   | $      | 1,081,095  |   |

----

|                                       |   | Numberof shares |      | Weightedaverageexerciseprice |   | Weightedaveragefair value |   |
|--------------------------------------------|--------|----------------------|-----------|------------------------------|--------|--------------------------------|--------|
|                                       |   |                 |      |                         |   |                           |   |
| Balance                  December 31, 2007 |   |                 | 3,000,000 |                         | $      | 0.25                           |   | $ | 0.16 |   |
| Exercised                                  |   |                 | -         |                         |   | -                              |   |   | - |   |
| Issued                                     |   |                 | -         |                         |   | -                              |   |   | - |   |
| Forfeited                                  |   |                 | -         |                         |   | -                              |   |   | - |   |
|                                       |   |                 |           |                         |   |                                |   |   |  |   |
| Balance                  June 30, 2008     |   |                 | 3,000,000 |                         | $      | 0.25                           |   | $ | 0.16 |   |

**:**

| ExercisePrice |   | WeightedAverageNumberOutstanding |      | WeightedAverageContractualLife |   | WeightedAverageExercisePrice |   |
|---------------|--------|----------------------------------|-----------|--------------------------------|--------|------------------------------|--------|
|          |   |                             |      |                           |   |                         |   |
| $.20          |   |                             | 1,000,000 |                           |   | 2.8                  years   |   | $ | .20 |   |
| $.27          |   |                             | 2,000,000 |                           |   | 3.0                  years   |   | $ | .27 |   |
|          |   |                             | 3,000,000 |                           |   |                              |   |   |  |   |

----

**Item      2.****Management’s      Discussion and Analysis of Financial Condition and Results of Operations/Plan      of      Operations **

**Management’s      Discussion and Analysis of Financial Condition and Results of      Operations**

**Liquidity      and Capital Resources**

| · | Sell                or dispose of our assets, if any; |
|--------|-------------------------------------------------------|

| · | Pay                our liabilities in order of priority, if we have available cash to                pay                such liabilities; |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------|

| · | If                any cash remains after we satisfy amounts due to our creditors, distribute                any remaining cash to our shareholders in an amount equal to the                net                market value of our net assets; |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | File                a Certificate of Dissolution with the State of California to dissolve                our                corporation and close our business; |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Make                the appropriate filings with the Securities and Exchange Commission                so                that we will no longer be required to file periodic and other required                reports with the Securities and Exchange Commission, if, in fact,                we are a                reporting company at that time; and |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| · | Make                the appropriate filings with the National Association of Security                Dealers                to effect a delisting of our common stock, if, in fact, our common                stock                is trading on the Over-the-Counter Bulletin Board at that                time. |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Results      of Operations – Comparison      of      Three Month Periods ending June 30, 2007 and June 30,      2008**

**Results      of Operations – Comparison of Six Month Periods ending June 30, 2007 and June      30, 2008**

**Off-Balance      Sheet Arrangements**

| · | an                obligation under a guarantee contract;                                                                                                                                                                                                        |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                            |
| · | a                retained or contingent interest in assets transferred to the                unconsolidated entity or similar arrangement that serves as credit,                liquidity or market risk support to such entity for such                assets; |
|   |                                                                                                                                                                                                                                                            |
| · | any                obligation, including a contingent obligation, under a contract that                would                be accounted for as a derivative instrument,                or;                                                                     |

| · | any                obligation, including a contingent obligation, arising out of a variable                interest in an unconsolidated entity that is held by us and material                to us                where such entity provides financing, liquidity, market risk or credit                risk support to, or engages in leasing, hedging or research and                development services with us.” |
|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**Plan      of Operations**

| Type                of Expenditure                                                                                             |   | Total Expenditure                  |    | Monthly Expenditure |   |
|--------------------------------------------------------------------------------------------------------------------------------|--------|----------------------------------------------|---------|--------------------------|--------|
|                                                                                                                           |   |                                         |    |                     |   |
| Salaries*                                                                                                                      |   | $                                            | 175,000 |                     | $      | 14,583 |   |
|                                                                                                                           |   |                                         |         |                     |   |  |   |
| Travel                related expenses for our Chief Executive Officer pertaining                to research and due diligence |   |                                         | 40,000  |                     |   | 3,333 |   |
|                                                                                                                           |   |                                         |         |                     |   |  |   |
| Professional                Fees -Legal and Accounting                                                                         |   |                                         | 165,000 |                     |   | 13,750 |   |
|                                                                                                                           |   |                                         |         |                     |   |  |   |
| Total                                                                                                                          |   | $                                            | 380,000 |                     | $      | 31,666 |   |

| Type                of Expenditure                                   |   | Total Expenditure                  |      | Monthly Expenditure |   |
|----------------------------------------------------------------------|--------|----------------------------------------------|-----------|--------------------------|--------|
|                                                                 |   |                                         |      |                     |   |
| Salaries                                                             |   | $                                            | 350,000   |                     | $      | 29,167 |   |
|                                                                 |   |                                         |           |                     |   |  |   |
| Clinical                Trial expenses                               |   |                                         | 1,045,000 |                     |   | 87,083 |   |
|                                                                 |   |                                         |      |                     |   |   |   |
| R                & D Expenses                                    |   |                                         | 394,000   |                     |   | 32,833 |   |
|                                                                 |   |                                         |      |                     |   |   |   |
| Cost                of raw materials and production                  |   |                                         | 236,000   |                     |   | 19,667 |   |
|                                                                 |   |                                         |           |                     |   |  |   |
| Operating                Expenses (Rent, Supplies, Utilities, etc..) |   |                                         | 50,000    |                     |   | 4,167 |   |
|                                                                 |   |                                         |           |                     |   |  |   |
| Total                                                                |   | $                                            | 2,075,000 |                     | $      | 172,917 |   |

| Type                of Expenditure                      |   | TotalExpenditure |    | MonthlyExpenditure |   |
|-------------------------------------------------------------------|--------|------------------|---------|--------------------|--------|
|                                                              |   |             |    |               |   |
| Operating                    Expenses (Rent, supplies, utilities) |   | $                | 50,000  |               | $      | 4,167 |   |
| Salaries                (President)                     |   |             | 70,000  |               |   | 5,833 |   |
| Total:                                                  |   | $                | 120,000 |               | $      | 10,000 |   |

----

|   | · | On                January 24, 2006, we obtained NanoLogix’s intellectual property pertaining                to the manufacture of test kits for the rapid isolation, detection                and                antibiotic sensitivity testing of certain microbacteria, which includes                reassignment to us of 11 key patents protecting the diagnostics test                kit                technology and NanoLogix licensing to us, and the remaining 18 patents                that protect the diagnostics test kit                technology. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                February 2006, we completed the initial funding of ReceptoPharm in                the                amount of $2,000,000. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January 2006, we established Designer Diagnostics to sell NonTuberculois                Mycobacterium test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Designer                Diagnostics held a Continuing Medical Education Seminar at the Mahatma                Gandhi Institute in India on March 24, 2006 during the World Stop                TB Day.                At that meeting, Designer Diagnostics officially began marketing                their                test kits for the rapid isolation, detection and antibiotic-sensitivity                testing of microbacteria. In March 2006, we made our first sales                of                Designer Diagnostics’ test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                May 2006, ReceptoPharm received approval from the Medicines Health                and                Regulatory Agency (MHRA) for its application of human clinical trials                for                the treatment of Adrenomyeloneuropathy (AMN). The MHRA is the medical                regulatory agency within the British Department of                Health. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | From                March and April of 2006, ReceptoPharm published two clinical trials                on the                use of their technology for the treatment of                pain. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                June 2006, ReceptoPharm published the results of their EAE rat model                of  MS, which showed that their drug, RPI-78M, had promising results                in an accepted animal model of the                disease. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                October of 2006, ReceptoPharm received Ethics Committee approval                in the                United Kingdom to begin its Phase IIb human clinical trial for the                treatment of AMN. This approval allows for the late Phase II/early                Phase                III (Iib/IIIa) trial to begin. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | From                November 29, 2006 to December 2, 2006, ReceptoPharm presented their                analgesic research on RPI-78M at the International Conference on                Neurotoxins (ICoN) in Hollywood, Florida. |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, we completed a series of microarray studies with                various                companies that ReceptoPharm has agreements with pertaining to                ReceptoPharm’s anti-viral drug. The microarray studies indicated that the                exposure of healthy immune T-cells to our antiviral drugs activates                the                primary immune mechanisms. The expression of one such immune trigger,                interferon gamma, is increased by as much as 20 times, acting as                an                effective antiviral agent, but without the significant negative clinical                side effects of other interferon-based therapies. This may explain                the                broad antiviral activity observed with these types of agents. Based                upon                this data, these products could conceivably be used to substitute                for the                flu shot in winter or protect against other contagious viral diseases                when                vaccines are not readily available. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, Designer Diagnostics received positive results from                its                in-vitro analysis of its Tuberculosis (TB) test kit. Normal culturing                methods can take as long as 10 weeks to produce results, where Designer                Diagnostics test kits have shown similar results within 10                days. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                January of 2007, ReceptoPharm began its Phase IIb human clinical                trial for                the treatment of AMN. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                February of 2007, ReceptoPharm expanded their antiviral clinical                research                into Mexico and Peru where RPI-MN was used in early clinical studies.                ReceptoPharm seeks to conduct two Phase II antiviral trials each                with a                primary duration of 3-4 months. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                March of 2007, Designer Diagnostics engaged the U.S. Commercial Service                to                help build international sales of its diagnostic test                kits. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                March 7, 2007, ReceptoPharm’s signed a letter of intent to create a Joint                Venture with Nan gene Biotechnology, a Chinese biotech company. The                proposed joint venture will develop the antiviral drug, RPI-MN, for                the Chinese market. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                March of 2007, ReceptoPharm published an article in the Critical                Reviews                in Immunology special conference issue. The article, entitled                “Alpha-Cobratoxin”, discussed Alpha-Cobratoxin as a possible therapy for                Multiple Sclerosis, reviews the literature leading to the development                for                this application, and discusses the background and reasoning behind                ReceptoPharm’s research on its treatment for Multiple Sclerosis                (MS). |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                March 27, 2007, we completed our first licensing payment on behalf                of                Designer Diagnostics to NanoLogix for the patents protecting Designer                Diagnostics’ test kits. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | On                April 11, 2007, ReceptoPharm filed a patent for method of treating                autoimmune diseases, including MS and Rheumatoid                Arthritis. |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                April 2007, ReceptoPharm completed its initial discussions with Zhong                Xin                Dong Tai Co., Ltd (“Nanogene Biotechnology”) to develop RPI-MN for the                China market. RPI-MN is ReceptoPharm’s drug candidate being researched for                the treatment of HIV/AIDS and other viral disorders. According to                a signed                Memorandum of Understand between ReceptoPharm and Nanogene Biotechnology.                ReceptoPharm will need to confirm safety and efficacy of RPI_MN by                completing pre-clinical studies at Soochow University located in                China.                Nanogene Biotechnology will provide the drug raw material and ReceptoPharm                will modify the products and provide the proper study protocols.                Upon                successful completion of the pre-clinical studies, ReceptoPharm and                Nanogene Biotechnology will proceed with clinical trials aimed at                gaining                full regulatory approval in China. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                May 2, 2007, Designer Diagnostics announced that it would conduct                clinical                trials for their Tuberculosis and NonTuberculois Mycobacterium diagnostic                test kits at the National Jewish Medical and Research Center in Denver,                Colorado. The purpose of the clinical trials is to validate the efficacy                of the test kits for use with Tuberculosis and Non-Tubernulosis                Mycobacterium patients as well as for environmental testing. The                clinical                trials for Designer Diagnostics are the final step required by the                FDA                prior to applying for FDA regulatory approval of the test kits. The                studies are ongoing with plans to complete testing throughout 2008. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                May 2007, Designer Diagnostics completed the upgrade of its Tuberculosis                diagnostic test kits enabling such the test kits to show more rapid                and                reliable results. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | During                July 2007, ReceptoPharm successfully completed enrollment in its                phase llb                human clinical trial for the treatment of AMN. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                August of 2007, ReceptoPharm successful results on the use of their                technology for the treatment of pain. The latest data demonstrated                that                RPI-78 was as effective as morphine at blocking pain signals in that                part                of the brain that signals the presence of pain. It was also confirmed                that                the drug did not use an opioid mechanism. Moreover, the duration                of                RPI-78’s effect was superior to                morphine’s. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                November 2007, the Designer Diagnostics test kit technology was showcased                at the 38th Union World Conference on Lung Health in South Africa.                The                test kits were used to isolate NTM from clinical samples of 300 AIDS                patients and for the first time ever on the Indian subcontinent,                M.                Wolinskyi was successfully isolated in clinical samples. In addition,                these test kits were also used for the first time to isolate NTM                from soil                and water samples collected from the environment of patients with                NTM                disease. |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                November 2007, Designer Diagnostics was featured in an article published                in the International Journal of TB and Lung Diseases. The article,                which                was authored by leading NonTuberculous Mycobacterium (NTM) research                scientist, Dr. Rahul Narang, covered Designer Diagnostics’ paraffin                culture technology to isolate NTM. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | In                December 2007, ReceptoPharm successfully completed its six-month                patient                crossover in the Phase IIb/IIIa clinical trial for the treatment                of                Adrenomyeloneuropathy (AMN). |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                December 27, 2007 the Company expanded its licensing agreement with                NanoLogix, Inc., to include intellectual property for the use of                testing                the environment for NonTuberculous Mycobacterium                (NTM). |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | In                February 2008, Designer Diagnostics started marketing the first-ever                environmental test kit for the detection of Nontuberculous Mycobacteria                (NTM) in water and soil. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | On                April 10, 2008, we completed the acquisition of ReceptoPharm through                our                purchase of their remaining 61.9% interest. ReceptoPharm is now our                wholly                owned subsidiary and will act as our Drug Discovery division.                                                                  |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                May 19, 2008, we announced today that ReceptoPharm, Inc. had received                approval from the Florida Department of Agriculture and Consumer                Services                to conduct trials of its leading antiviral drug candidate, RPI-MN,                as a                treatment for Feline Leukemia Virus (FeLV). |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                July 19, 2008, we announced the successful completion of ReceptoPharm’s                Phase IIb/IIIa clinical trial of its leading drug candidate for                neurological and autoimmune disorders, RPI-78M, as a treatment for                Adrenomyeloneuropathy (AMN).                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                August 6, 2008, we announced that ReceptoPharm had renewed its                collaborative agreement with the Centers for Disease Control and                Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy                for                Rabies.                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                                                             |
|   | · | On                August 14, 2008, we announced initial positive safety data from                ReceptoPharm’s Phase IIb/IIIa clinical study of RPI-78M for treating                Adrenomyeloneuropathy (AMN).                                                                                                                                          |

*Designer      Diagnostics, Inc.*

| · | Hospitals; |
|--------|------------|

| · | Pharmaceutical                companies; |
|--------|------------------------------------------|

| · | Biotechnology                companies; |
|--------|-----------------------------------------|

| · | Medical                device distributors; |
|--------|---------------------------------------------|

| · | Governmental                organizations;                                                                         |
|--------|--------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                               |
| · | Environmental                testing facilities; and                                                               |
|   |                                                                                                               |
| · | Government                water and soil testing facilities at the local, state and federal                levels. |

----

*ReceptoPharm*

| · | Recruitment                of 20 patients with AMN; |
|--------|-----------------------------------------------------|

| · | Administering                ReceptoPharm’s AMN drug under development;                and |
|--------|--------------------------------------------------------------------------------------------------|

| · | Monitoring                patients throughout a 15-month                protocol. |
|--------|-----------------------------------------------------------------------------------|

**Item      3. Quantitative and Qualitative Disclosures About Market Risk**

**Item      4T. Controls and Procedures**

----

**PART      II.**
**OTHER      INFORMATION**
** **

**Item      1.**
**Legal      Proceedings **

**Item      2.**
**Unregistered      Sales of Equity Securities and Use of Proceeds **

**Item      3. **
**      Defaults Upon Senior Securities**

**Item      4. **
**      Submission of Matters to a Vote of Security Holders **

----

**Item      5.**
**Other      Information **

*ReceptoPharm      becomes our Wholly Owned Subsidiary*

***Background***

***The      Agreement***

*Appointment      of Directors *

***Paul      F. Reid, PhD***

----

***Harold      H. Rumph***

** **

**Item      6.**
**Exhibits      **

| Exhibit                No. |   | Title                                                                                                                                                                                                                                      |
|----------------------------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                       |   |                                                                                                                                                                                                                                       |
| 31.1                       |   | Certification                of Chief Executive Officer and Chief Financial Officer pursuant to                Section                302 of the Sarbanes-Oxley Act of 2002.                                                               |
|                       |   |                                                                                                                                                                                                                                       |
| 32.1                       |   | Certification                of Chief Executive Officer and Chief Financial Officer pursuant to                18                U.S.C. Section 1350, as adopted pursuant to Section 906 of the                Sarbanes-Oxley Act of 2002. |

**SIGNATURES**

| Dated:                August 19, 2008                                                                                                |   |   |   |
|--------------------------------------------------------------------------------------------------------------------------------------|--------|--------|--------|
|                                                                                                                                 |   |   |   |
| NUTRA                PHARMA CORP.                                                                                                    |   |   |   |
| Registrant                                                                                                                           |   |   |   |
|                                                                                                                                 |   |   |   |
| /s/ Rik                J. Deitsch                                                                                               |   |   |   |
| Rik                J. Deitsch                                                                                                        |   |   |   |
| Chief                Executive Officer/Principal Financial OfficerChief                Financial Officer/Principal Financial Officer |   |   |   |

----